Global Ankylosing Spondylitis Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Ankylosing Spondylitis Market was valued at $6.8 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 6.6% CAGR, to an estimated market size of $9.4 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The market encompasses pharmaceuticals, biologics, and biosimilars used for the treatment of Ankylosing Spondylitis, a chronic inflammatory condition primarily affecting the axial skeleton. The scope includes various drug classes such as TNF inhibitors, IL-17 inhibitors, NSAIDs, and JAK inhibitors, while excluding non-pharmacological physical therapy and surgical interventions.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Ankylosing Spondylitis Market in the period 2025-30:
- Integration of AI-enabled MRI scoring and machine learning to improve diagnostic accuracy and reduce the time to treatment initiation.
- Increased adoption of biosimilars following patent expirations of major biologics, driving volume growth through improved affordability.
- Growing patient preference for oral JAK inhibitors as a convenient, non-injectable alternative to traditional biologic therapies.
- Introduction of dual-target inhibitors, such as IL-17A/F blockers, providing superior efficacy for patients resistant to first-line TNF therapy.
- A shift toward personalized medicine utilizing genetic biomarkers like HLA-B27 to predict treatment response and tailor therapeutic strategies.
- Expansion of specialist density and hospital infrastructure in emerging markets, particularly across the Asia-Pacific region.
- Rising utilization of digital health tools and mobile apps for remote monitoring of disease activity and medication adherence.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia Pacific
- Rest of World
Segments
- TNF Inhibitors
- IL Inhibitors
- NSAIDs
- JAK Inhibitors & Others